Theravance, Pfizer in License Agreement
23 Dezembro 2019 - 11:07AM
Dow Jones News
By Michael Dabaie
Theravance Biopharma Inc. (TBPH) and Pfizer Inc. (PFE) said they
entered into a global license agreement for Theravance's
preclinical program for skin-targeted, locally-acting pan-Janus
kinase, or JAK, inhibitors that can be rapidly metabolized.
Theravance will receive an upfront cash payment of $10 million
and will be eligible to receive up to an additional $240 million in
development and sales milestone payments from Pfizer.
Theravance will also be eligible to receive royalties on
worldwide net sales of any potential products emerging from the
program.
JAK inhibitors are currently approved for the treatment of a
range of inflammatory diseases including rheumatoid arthritis,
psoriatic arthritis, myelofibrosis, and ulcerative colitis.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
December 23, 2019 08:52 ET (13:52 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Pfizer (NYSE:PFE)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024